Ergomed, a specialised clinical development company based in Frankfurt, Germany, has consolidated its presence in Eastern Europe and Central Asia by opening a new office in Russia.
The Moscow office will be run by Dr Sergei Drapkin, newly appointed as managing director of Ergomed Russia. It will support Ergomed’s existing operations in Russia, Ukraine, Kazakhstan and Belorussia, emerging markets with “very significant potential for high patient recruitment”, the company noted.
Ergomed has been carrying out clinical trials in the region for some years now and has successfully integrated its Study Site Management system in Central and Eastern Europe, delivering faster patient recruitment and improved data quality, it pointed out. The company also cited the quality of local clinical research in Ergomed’s focus areas of neurology, oncology and immunology, “given the generally high standard of medical training and the concentration of medical expertise in a few centres”.
Dr Drapkin previously worked for Quintiles Transnational, co-founding the US contract research organisation’s Moscow office. In more than 10 years with Quintiles, he also headed up the company’s strategic group for assessing the feasibility of clinical research programmes in Central and Eastern Europe and the Middle East.
Ergomed’s business model spans both contract clinical research and co-development partnerships with pharmaceutical and biotechnology companies in the fields of neurology, oncology and immunology.